Sébastien Godat1, Fabrice Caillol2, Aurélie Autret3, Erwan Bories2, Christian Pesenti2, Jean Philippe Ratone2, Chiara De Cassan2, Flora Poizat4, Marc Giovannini2. 1. Division of Gastroenterology, Paoli-Calmettes Institute, 232 Boulevard Sainte Marguerite - BP 156, 13273, Marseille Cedex 9, France. tagodat@gmail.com. 2. Division of Gastroenterology, Paoli-Calmettes Institute, 232 Boulevard Sainte Marguerite - BP 156, 13273, Marseille Cedex 9, France. 3. Division of Biostatistics, Paoli-Calmettes Institute, Marseille, France. 4. Division of Pathology, Paoli-Calmettes Institute, Marseille, France.
Abstract
BACKGROUND: Endotherapy in cases of neoplastic Barrett esophagus (BE) relapse after successful initial endoscopic management is commonly accepted, but few studies analyze this topic and also take into account the metachronous lesions. AIMS: To evaluate the efficiency of endotherapy in the case of neoplastic BE relapse after successful complete endoscopic eradication of neoplastic BE and metaplastic BE. METHODS: Retrospective review of medical records was collected in a computerized and prospective manner between 2000 and 2015, in a single tertiary care center. Recurrence was defined by histological presence of high-grade dysplasia or superficial adenocarcinoma at least 6 months after the end of successful initial endotherapy. RESULTS: Eighteen patients were assessed (1F/17 M). Delay between initial treatment and relapse was 16.6 months (range 6-33). Endotherapy for relapse obtained a sustained and complete remission for 8/18 (44%) patients, with an average endoscopic follow-up of 28 months. The complication rate of endotherapy was 6%. Surgical management was required in 33% (2 pT2N0M0, 2 pTisN0M0, 1 pTm2N0M0 and 1 pTm3N0M0) and salvage radiochemotherapy in 17% (3/18). One patient treated by 6 sessions of ER was considered as a failure given the multiple sessions of endotherapy. Multivariate analysis showed that length of BE (>5 cm), late stenosis adverse events and the quality of vertical margin during initial ER are predictive factors for disease-free survival (p value < 0.01, Hazard Ratio up to 0.076). CONCLUSION: Endotherapy could be a treatment for management of neoplastic BE relapse, but should be carefully used, with strict follow-up.
BACKGROUND: Endotherapy in cases of neoplastic Barrett esophagus (BE) relapse after successful initial endoscopic management is commonly accepted, but few studies analyze this topic and also take into account the metachronous lesions. AIMS: To evaluate the efficiency of endotherapy in the case of neoplastic BE relapse after successful complete endoscopic eradication of neoplastic BE and metaplastic BE. METHODS: Retrospective review of medical records was collected in a computerized and prospective manner between 2000 and 2015, in a single tertiary care center. Recurrence was defined by histological presence of high-grade dysplasia or superficial adenocarcinoma at least 6 months after the end of successful initial endotherapy. RESULTS: Eighteen patients were assessed (1F/17 M). Delay between initial treatment and relapse was 16.6 months (range 6-33). Endotherapy for relapse obtained a sustained and complete remission for 8/18 (44%) patients, with an average endoscopic follow-up of 28 months. The complication rate of endotherapy was 6%. Surgical management was required in 33% (2 pT2N0M0, 2 pTisN0M0, 1 pTm2N0M0 and 1 pTm3N0M0) and salvage radiochemotherapy in 17% (3/18). One patient treated by 6 sessions of ER was considered as a failure given the multiple sessions of endotherapy. Multivariate analysis showed that length of BE (>5 cm), late stenosis adverse events and the quality of vertical margin during initial ER are predictive factors for disease-free survival (p value < 0.01, Hazard Ratio up to 0.076). CONCLUSION: Endotherapy could be a treatment for management of neoplastic BE relapse, but should be carefully used, with strict follow-up.
Authors: K Nadine Phoa; Roos E Pouw; Frederike G I van Vilsteren; Carine M T Sondermeijer; Fiebo J W Ten Kate; Mike Visser; Sybren L Meijer; Mark I van Berge Henegouwen; Bas L A M Weusten; Erik J Schoon; Rosalie C Mallant-Hent; Jacques J G H M Bergman Journal: Gastroenterology Date: 2013-03-28 Impact factor: 22.682
Authors: Oliver Pech; Elfriede Bollschweiler; Hendrik Manner; Jessica Leers; Christian Ell; Arnulf H Hölscher Journal: Ann Surg Date: 2011-07 Impact factor: 12.969
Authors: Lorenza Alvarez Herrero; Frederike G I van Vilsteren; Roos E Pouw; Fiebo J W ten Kate; Mike Visser; Cornelis A Seldenrijk; Mark I van Berge Henegouwen; Paul Fockens; Bas L A M Weusten; Jaques J G H M Bergman Journal: Gastrointest Endosc Date: 2011-02-02 Impact factor: 9.427
Authors: Roos E Pouw; Katja Wirths; Pierre Eisendrath; Carine M Sondermeijer; Fiebo J Ten Kate; Paul Fockens; Jacques Devière; Horst Neuhaus; Jacques J Bergman Journal: Clin Gastroenterol Hepatol Date: 2009-08-11 Impact factor: 11.382
Authors: M Giovannini; E Bories; C Pesenti; V Moutardier; G Monges; C Danisi; B Lelong; J R Delpero Journal: Endoscopy Date: 2004-09 Impact factor: 10.093
Authors: Jennifer Chennat; Vani J A Konda; Andrew S Ross; Alberto Herreros de Tejada; Amy Noffsinger; John Hart; Shang Lin; Mark K Ferguson; Mitchell C Posner; Irving Waxman Journal: Am J Gastroenterol Date: 2009-08-18 Impact factor: 10.864
Authors: Rehan J Haidry; Mohammed A Butt; Jason Dunn; Matthew Banks; Abhinav Gupta; Howard Smart; Pradeep Bhandari; Lesley Ann Smith; Robert Willert; Grant Fullarton; Morris John; Massimo Di Pietro; Ian Penman; Marco Novelli; Laurence B Lovat Journal: World J Gastroenterol Date: 2013-09-28 Impact factor: 5.742
Authors: R J Haidry; M A Butt; J M Dunn; A Gupta; G Lipman; H L Smart; P Bhandari; L Smith; R Willert; G Fullarton; M Di Pietro; C Gordon; I Penman; H Barr; P Patel; N Kapoor; J Hoare; R Narayanasamy; Y Ang; A Veitch; K Ragunath; M Novelli; L B Lovat Journal: Gut Date: 2014-12-24 Impact factor: 23.059
Authors: Sébastien Godat; Mariola Marx; Fabrice Caillol; Maxime Robert; Aurélie Autret; Erwan Bories; Christian Pesenti; Jean Philippe Ratone; Alain Schoepfer; Flora Poizat; Marc Giovannini Journal: Ann Gastroenterol Date: 2021-12-06